Therapy for Pulmonary Arterial Hypertension: Glance on Nitric Oxide Pathway
Authors:
Open Access
- 12 November 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 12
Abstract
Pulmonary arterial hypertension (PAH) is a severe disease with a resultant increase of the mean pulmonary arterial pressure, right ventricular hypertrophy and eventual death. Research in recent years has produced various therapeutic options for its clinical management but the high mortality even under treatment remains a big challenge attributed to the complex pathophysiology. Studies from clinical and non-clinical experiments have revealed that the nitric oxide (NO) pathway is one of the key pathways underlying the pathophysiology of PAH. Many of the essential drugs used in the management of PAH act on this pathway highlighting its significant role in PAH. Meanwhile, several novel compounds targeting on NO pathway exhibits great potential to become future therapy medications. Furthermore, the NO pathway is found to interact with other crucial pathways. Understanding such interactions could be helpful in the discovery of new drug that provide better clinical outcomes.Keywords
Funding Information
- National Natural Science Foundation of China (81973324)
This publication has 130 references indexed in Scilit:
- S-nitrosylation of ERK inhibits ERK phosphorylation and induces apoptosisScientific Reports, 2013
- Bone Morphogenetic Protein Receptor II Is a Novel Mediator of Endothelial Nitric-oxide Synthase ActivationJournal of Biological Chemistry, 2011
- Soluble Guanylate Cyclase as an Emerging Therapeutic Target in Cardiopulmonary DiseaseCirculation, 2011
- Disruption of the Apelin-APJ System Worsens Hypoxia-Induced Pulmonary HypertensionArteriosclerosis, Thrombosis, and Vascular Biology, 2011
- Mice deficient in Mkp-1 develop more severe pulmonary hypertension and greater lung protein levels of arginase in response to chronic hypoxiaAmerican Journal of Physiology-Heart and Circulatory Physiology, 2010
- Rosiglitazone via upregulation of Akt/eNOS pathways attenuates dysfunction of endothelial progenitor cells, induced by advanced glycation end productsBritish Journal of Pharmacology, 2009
- Vascular cell signaling by membrane estrogen receptorsSteroids, 2008
- Pathology of Pulmonary HypertensionClinics in Chest Medicine, 2007
- Rho Kinase Inhibition Improves Endothelial Function in Human Subjects With Coronary Artery DiseaseCirculation Research, 2006
- The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholineNature, 1980